Literature DB >> 10965788

Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia.

J Cid1, M Revilla, A Cervera, F Cervantes, E Muñoz, I Ferrer, E Montserrat.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating disorder of the central nervous system usually affecting immunocompromised individuals and is due to infection of the oligodendrocytes by the JC virus. A case of PML in a chronic lymphocytic leukemia (CLL) patient treated with fludarabine is reported, representing the second such instance in which the diagnosis of the neurological disorder was established by brain biopsy. A 61-year-old man with a 14-year history of B-cell type CLL, for which he had received chlorambucil therapy 10 years earlier, developed progressive paresis of both left extremities at 7 months of receiving low doses of oral fludarabine, when his CD4 count has decreased to 0.08 x 10(9)/l. Cranial magnetic resonance imaging revealed a subcortical focal lesion at the right precentral gyrus and a focal lesion at the right thalamus, and a stereotactic brain biopsy showed pathological findings consistent with PML, namely severe myelin breakdown, reactive astrocytosis, and abnormal, huge glial cells with large bizarre nuclei showing granular basophilic inclusions, whereas the presence of the JC virus was demonstrated by in situ hybridization. The present case, in addition to a few previously reported, calls attention to the possibility that severe neurological side effects can be associated with the immunosuppression provoked by the use of fludarabine in CLL patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965788     DOI: 10.1007/s002779900149

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

Review 1.  Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy.

Authors:  Leslie J Marshall; Eugene O Major
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-17       Impact factor: 4.147

2.  Reversible parkinsonism in a patient with progressive multifocal leucoencephalopathy.

Authors:  Caroline H Williams-Gray; Sani H Aliyu; Andrew M L Lever; Andrew F Dean; Graham G Lennox
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04       Impact factor: 10.154

Review 3.  Oral fludarabine.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

Review 5.  Central Nervous System Complications in Children Receiving Chemotherapy or Hematopoietic Stem Cell Transplantation.

Authors:  Duccio Maria Cordelli; Riccardo Masetti; Daniele Zama; Francesco Toni; Ilaria Castelli; Emilia Ricci; Emilio Franzoni; Andrea Pession
Journal:  Front Pediatr       Date:  2017-05-15       Impact factor: 3.418

Review 6.  A Review of Acute and Long-Term Neurological Complications Following Haematopoietic Stem Cell Transplant for Paediatric Acute Lymphoblastic Leukaemia.

Authors:  Melissa Gabriel; Bianca A W Hoeben; Hilde Hylland Uhlving; Olga Zajac-Spychala; Anita Lawitschka; Dorine Bresters; Marianne Ifversen
Journal:  Front Pediatr       Date:  2021-12-23       Impact factor: 3.418

7.  Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.

Authors:  Ann Janssens; Marc Boogaerts; Gregor Verhoef
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.